Biotech Values

[DewDiligence]

NVS is now disclosing its sales of everolimus to ABT for incorporation into the Xience/Promus stents. The amount was $67M in 3Q09 and $183M in the first nine months of 2009:

http://www.novartis.com/downloads/investors/sales-results/Q3-2009-report_EN.pdf (pages 37-38)

BSX’s Promus Element stent, soon to be launched outside the US, is made by BSX itself rather than by ABT; NVS will supply BSX directly with the everolimus coating for this stent.